The U.S. agreed to pay drugmaker Pfizer and German partner BioNTech nearly $2 billion for 100 million coronavirus vaccine doses if their candidate proves both safe and effective. Forgot account? Find RelSci relationships, employment history, board memberships, donations, awards, and more.President & Managing Director at Morgan Stanley Investment Management, Inc.Executive Director at Morgan Stanley Smith Barney LLCCo-Chairman, Co-President & Co-Chief Executive Officer at Morgan Stanley Smith Barney LLCChief Executive Officer, Morgan Stanley China at Morgan StanleyExecutive Director at Morgan Stanley Alternative Investment Partners LPStay informed and up-to-date on your network with RelSci news and business alerting service. The US coronavirus outbreak will “have a very long tail”, Morgan Stanley’s biotech analyst Matthew Harrison writes, in a note dated Sunday, striking a cautious tone on the timeline for reopening the world’s largest economy. Recovering from this acute period in the outbreak is just the beginning and not the end. Wood stay days at a savings of $5,500 per patient, or $200,000 What inefficiency could IOT address? Market Trends. Create New Account. We want to hear from you.The analyst has gained a wide following on Wall Street for his success in predicting the course of the pandemic and government responses. See more of Jim Lacamp, Sr Vice President, Financial Advisor at Morgan Stanley on Facebook. From volatility and geopolitics to economic trends and investment outlooks, stay informed on the key developments shaping today's markets. At Morgan Stanley, we lead with exceptional ideas. Reviews. “It will require turning on and off various forms of social distancing and will only come to an end when vaccines are available, in the spring of 2021 at the earliest”, he remarks, on the way to predicting that once we see a sustained decline in new cases in coastal areas, there will be a “second peak” in other regions. [About] 150,000 daily new cases are possible without better control of the virus."Harrison previously projected a "second wave" in the autumn with daily new cases totaling between 40,000 and 50,000 nationwide. Morgan Stanley: “While we understand the desire for optimism, we also caution that the US outbreak is far from over. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.An error has occurred, please try again later.He expects the FDA to make a decision by March.https://www.barrons.com/articles/buy-biogen-stock-says-morgan-stanley-because-the-time-is-right-51595859634Biogen trades at 8.1 times earnings expected over the next 12 months, below its 5-year average of 11.7 times earnings, according to FactSet. or. Matthew K. Harrison is affiliated with Morgan Stanley, Morgan Stanley & Co. LLC, UBS Warburg LLC (US), Highland Capital Management LP, Cummings Bay Advisors LLC Stay informed and up-to-date on your network with RelSci news and business alerting service. Matthew Harrison, Morgan Stanley's head of biotech research, discusses the worrying surge in COVID-19 cases in several states, and says if lockdown measures are reimposed in the U.S., they're likely to be more regionally-based than statewide or nationally. Jim Lacamp, Sr Vice President, … It’s time to take a gamble on Biogen stock, according to Morgan Stanley analyst Matthew Harrison. Although New York continues to flatten the curve in terms of coronavirus numbers, talks of re-opening the economy have fallen flat. About. At Morgan Stanley, we lead with exceptional ideas. The stock closed Friday at $272.33.Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved (See...Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market. Sarepta shares were down 5 percent at the start of the week against a biotech index that was up 3 percent after the...Although Biogen Inc (NASDAQ: BIIB) will face generic competitors for Tecfidera in the near term, the pricing in of aducanumab success may drive the stock to the mid-$300s, according to Morgan Stanley.The Biogen Analyst: Matthew Harrison upgraded Biogen from Underweight to Overweight and raised the...Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab.The AnalystsMizuho Securities analyst Salim Syed...Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.As the year draws to a close, Morgan Stanley said stock selection is the key to biotech investing in 2020 as drug pricing and election fears wane, offering incremental upside for...Moderna Inc (NASDAQ: MRNA) shares were bulldozing their way toward record highs Wednesday in reaction to the publication in the New England Journal of Medicine of detailed interim Phase 1 data for mRNA-1273, its SARS-CoV2 vaccine candidate.The Moderna Analysts: BofA Securities analyst...Gilead Sciences, Inc. (NASDAQ: GILD) reported after the market close Thursday with results that left investors uninspired. The AnalystsMorgan Stanley analyst Matthew Harrison maintained an Equal-weight rating on Gilead with a $75 price target.Baird analyst Brian Skorney maintained...With about eight coronavirus vaccine candidates in clinical trials and 110 more in clinical testing, the race to a commercial product is intensifying.